Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training
CompletedNot applicableNCT05573685
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).
Study details
- Official title
- A Randomized, Controlled, Single-Blind, Exploratory Basket Study to Evaluate the Effects of a DiNaMo™ Component Training in Adults With Chronic Pain-Related Disorders
- Conditions
- Rheumatoid Arthritis
- Diabetic Neuropathy
- Fibromyalgia
- Irritable Bowel Syndrome
- Interventions
- Device: DiNaMo Study App
- Device: Placebo App
- Sponsor
- Click Therapeutics, Inc.
- Start date
- 2022-10-10
- Primary completion
- 2023-02-06
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Meets indication-specific eligibility criteria as reported by the study participant with adequate clinical documentation * Self-reported average pain intensity during the last 7 days of ≥ 3 of 10 on the Numeric rating Scale (NRS scale) associated with the primary indication * Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form.) * Willing and able to comply with study protocol and assessments, evidenced by completion of the Screening Survey. * Lives in the United States. * Has an active email address and is willing and able to receive email messages. * Is the sole user of an iPhone with iPhone operating systems (iOS) 14 or later capabilities or a smartphone with an Android operating system (OS) 10 or later capabilities with cellular and/or internet access for the duration of the study period. Exclusion Criteria: * Has a comorbid acute pain condition, such as from current injuries * Participation in a clinical trial (including psychotherapy, mindfulness, cognitive training, or drug treatment) within the last 2 months * Initiation or change in primary disease-specific medication for 30 days prior to entering the study * Self-reported substance use disorder within the past 1 year * Daily use of opioids of 30 MME (Morphine Milligram Equivalents) or more * Substance use disorder within the past 1 year. * Initiation or change in central nervous system-active medication (e.g., antidepressants) during the last 2 months. * Participation in a clinical trial within the last 2 months. * Planning to introduce new therapies or change therapies during the study duration * Visual, dexterity or cognitive deficit so severe that precludes the use of an app per investigator judgment. * Severe psychiatric disorder involving a history of psychosis * Other significant medical condition that may confound the interpretation of findings
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05573685